Vijayakumar Javalkar
Vascular Neurology · Shreveport, LANPI 1124319744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 36.5% of the total.
Across 313 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$647
- Pfizer$329
- EMD Serono, Inc.$305
- Sunovion Pharmaceuticals Inc.$205
- Amgen$160
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 151 | $1,593 |
| Novartis | 36 | $647 |
| Pfizer | 27 | $329 |
| EMD Serono, Inc. | 13 | $305 |
| Sunovion Pharmaceuticals Inc. | 16 | $205 |
| Amgen | 11 | $160 |
| Acadia Pharmaceuticals Inc | 9 | $148 |
| Livanova USA, Inc. | 4 | $72 |
| Jazz Pharmaceuticals Inc. | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 5 | $67 |
| UCB, Inc. | 2 | $59 |
| Biogen | 3 | $55 |
| Argenx US, Inc. | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| AstraZeneca | 3 | $48 |
| SK Life Science, Inc. | 1 | $48 |
| Merz Pharmaceuticals, LLC | 2 | $47 |
| Lilly USA, LLC | 3 | $47 |
| Sanofi | 2 | $45 |
| Genentech USA, Inc. | 2 | $44 |
| Tanabe Pharma America, Inc. | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Lundbeck LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Cala Health, Inc. | 1 | $15 |
| GE HealthCare | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Greenwich Biosciences, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
How this compares
Too few vascular neurology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 11 | $108,096 |
| RytaryCarbidopa/Levodopa | 16 | $12,907 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 26 | $6,058 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 50 | $4,971 |
| Rasagiline Mesylate | 45 | $4,603 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 123 | $2,762 |
| Selegiline Hcl | 29 | $2,605 |
| AmantadineAmantadine Hcl | 33 | $896 |
| Entacapone | 14 | $699 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 29 | $649 |
| Primidone | 38 | $550 |
| Levetiracetam | 26 | $378 |
| Atorvastatin Calcium | 38 | $372 |
| Donepezil Hcl | 22 | $367 |
| Baclofen | 26 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $148 | $108,09611 claims |
| Amneal Pharmaceuticals LLCRytary | $31 | $12,90716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other vascular neurology in Shreveport
- Pankaj SharmaShreveport$3K
- Roger KelleyShreveport$3K
- Himanshu ChokhawalaShreveport$3K
- Priyadarshee PatelShreveport$2K
- Syed AbbasShreveport$346
- Gabriel VidalNew Orleans$167K
- Richard ZweiflerNew Orleans$5K
- Bryce CasteigneThibodaux$2K
- Ashok PoluBaton Rouge$2K
- Robert TrainorNew Orleans$824
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.